返回 
加入收藏
葛根素注射液联合胺碘酮治疗冠心病患者PCI术后并发心律失常的疗效分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 葛根素注射液联合胺碘酮治疗冠心病患者PCI术后并发心律失常的疗效分析 |
| TITLE： | |
| 摘要： | 目的：探讨葛根素注射液联合胺碘酮治疗冠心病患者行经皮冠状动脉介入治疗术（PCI）后并发心律失常的疗效和安全性。方法：回顾性分析80例PCI术后并发心律失常的冠心病患者资料，按照治疗方式不同分为观察组（40例）和对照组（40例）。所有患者围手术期及术后用药根据病情参照美国心脏病学会/美国心脏协会（AHA/ACC）制定的冠心病治疗指南。两组患者均予以常规对症治疗，与此同时，对照组患者给予胺碘酮注射液150 mg加入5％葡萄糖注射液20 ml中充分溶解，在15 min内缓慢静脉滴完，待病情得到缓解后按照胺碘酮的负荷量3 mg/kg，以1 mg/min的滴速缓慢静脉滴注，6 h后再以0.5 mg/min的滴速维持，24 h总量为1 200 mg，连续静脉滴注3 d+口服胺碘酮片0.2 g，tid，1周后减至0.2 g，bid；观察组患者在对照组治疗基础上给予葛根素注射液400 mg加入0.9％氯化钠注射液250 ml中静脉滴注，qd。两组疗程均为2周。观察两组患者临床疗效，治疗前后心率 （HR）、左心室射血分数（LVEF）、左室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD）及不良反应发生情况。结果：观察组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）。治疗前两组患者HR、LVEF、LVESD、LVEDD比较，差异均无统计学意义 （P＞0.05）；治疗后，两组患者HR、LVESD、LVEDD均显著低于同组治疗前，且观察组低于对照组， LVEF均显著高于同组治疗前，且观察组高于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较差异无统计学意义（P＞0.05）。结论：葛根素注射液联合胺碘酮治疗冠心病患者PCI术后并发心律失常的疗效较好，可以改善患者心功能，且不增加不良反应，安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe the efficacy and safety of Puerarin injection combined with amiodarone in the treatment of arrhythmia in patients with coronary heart disease （CHD） after CPI. METHODS： Date of 80 CHD patients with arrhythmia after PCI were retrospectively analyzed and divided into observation group （40 cases） and control group （40 cases） by different treatment methods. All patients in perioperative period and postoperative medication administrated according to the condition of AHA/ACC guidelines. Two groups were treated with conventional western medicine， based on it， control group received Amiodarone injection 150 mg， adding into 5％ Glucose injection 20 ml fully dissolved by slowly intravenous injection within 15 min， slowly intravenous injected with speed rate of 1 mg/min with load amiodarone of 3 mg/kg until disease had been eased， maintained 0.5 mg/min for 24 h of 1 200 mg after 6 h， intravenous infusion of Amiodarone injection for 3 d+oral administration of Amiodarone tablet 0.2 g， tid， reduced to 0.2 g after 1 week， bid. On the basis of control group， observation group received Puerarin injection 400 mg， adding into 0.9％ Sodium chloride injection 250 ml， intravenous infusion， once a day， and 2 groups were treated for 2 week. Clinical efficacy， heart rate （HR）， left ventricular ejection fraction （LVEF）， left ventricular end systolic diameter （LVESD） and left ventricular end-diastolic diameter （LVEDD） before and after treatment， and the incidence of adverse reactions in 2 groups were observed. RESULTS： The effective rate in observation group was significantly higher than control group， with statistical significance （P＜0.05）. Before treatment， there was no significant difference in the HR， LVEF， LVESD and LVEDD in 2 groups （P＞0.05）. After treatment， HR， LVESD and LVEDD were significantly lower than before， and observation group was lower than control group， LVEF was significantly higher than before， and observation group was higher than control group， with statistical significances （P＜0.05）. And there was no significant difference in the incidence of adverse reactions in 2 groups（P＞0.05）. CONCLUSIONS： The Puerarin injection combined amiodarone shows good efficacy in the treatment of CHD patients with arrhythmia after CPI， which can improve patients’ cardiac functions， does not increase the adverse reactions， with good safety. |
| 期刊： | 2016年第27卷第36期 |
| 作者： | 许加素，彭晓琳，李洪林 |
| AUTHORS： | XU Jiasu，PENG Xiaolin，LI Honglin |
| 关键字： | 葛根素注射液；胺碘酮；冠心病；介入治疗；心律失常；疗效；安全性 |
| KEYWORDS： | Puerarin injection； Amiodarone； Coronary heart disease； Intervention treatment； Cardiac arrhythmia； Efficacy； Safety |
| 阅读数： | 497 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
